Table 3.
Drug use according to daily defined dosages (DDD) and ATC codes.
| Characteristic | N | All Patients, N = 799 | QT ÷ Risk, N = 316 | QT + Risk, N = 483 |
|---|---|---|---|---|
| Number of prescription drugs, Median (IQR) | 799 | 9 (6–12) | 8 (5–11) | 9 (6–12) |
| Cummulative DDDs of QT-prolonging drugs according to CredibleMeds© (2024), Median (IQR) | 739 | 3.00 (1.88–4.76) | 2.19 (1.25–3.68) | 3.75 (2.28–5.33) |
| Patients with no data | 60 | 26 | 34 | |
| Number of psychotropic drugs associated with QT prolongation according to CredibleMeds© (2024), n (%) | 765 | |||
| 1 | 137 (18) | 112 (39) | 25 (5.2) | |
| 2 | 210 (27) | 100 (35) | 110 (23) | |
| 3 | 211 (28) | 51 (18) | 160 (33) | |
| 4 | 122 (16) | 14 (4.9) | 108 (23) | |
| 5 | 54 (7.1) | 5 (1.8) | 49 (10) | |
| 6 | 16 (2.1) | 0 (0) | 16 (3.3) | |
| 7 | 11 (1.4) | 2 (0.7) | 9 (1.9) | |
| 8 | 3 (0.4) | 1 (0.4) | 2 (0.4) | |
| 11 | 1 (0.1) | 0 (0) | 1 (0.2) | |
| Patients with no data | 34 | 32 | 2 | |
| Number of somatic drugs associated with QT prolongation according to CredibleMeds© (2024), n (%) | 386 | |||
| 1 | 229 (59) | 99 (61) | 130 (58) | |
| 2 | 98 (25) | 37 (23) | 61 (27) | |
| 3 | 44 (11) | 21 (13) | 23 (10) | |
| 4 | 10 (2.6) | 5 (3.1) | 5 (2.2) | |
| 5 | 4 (1.0) | 0 (0) | 4 (1.8) | |
| 6 | 1 (0.3) | 0 (0) | 1 (0.4) | |
| Patients with no data | 413 | 155 | 258 | |
| Cummulative DDDs of antidepressants (N06A), Median (IQR) | 369 | 1.50 (1.00–2.25) | 1.50 (1.00–2.38) | 1.50 (1.00–2.25) |
| Patients with no data | 430 | 181 | 249 | |
| Cummulative DDDs of antiepileptics (N03A), Median (IQR) | 258 | 0.67 (0.38–1.00) | 0.67 (0.40–1.00) | 0.67 (0.33–1.00) |
| Patients with no data | 541 | 230 | 311 | |
| Cummulative DDDs of antipsychotics (N05A, including lithium), Median (IQR) | 665 | 1.78 (0.75–3.00) | 1.17 (0.50–2.25) | 2.02 (1.00–3.38) |
| Patients with no data | 134 | 98 | 36 | |
| Cummulative DDDs of anxiolytics incl. benzodiazepines (N05B), Median (IQR) | 139 | 1.5 (0.9–3.5) | 1.5 (0.9–5.5) | 1.3 (0.7–2.7) |
| Patients with no data | 660 | 269 | 391 | |
| Cummulative DDDs of hypnotics excl. benzodiazepines (N05C), Median (IQR) | 195 | 1.00 (1.00–2.00) | 1.00 (1.00–1.50) | 1.00 (1.00–2.00) |
| Patients with no data | 604 | 229 | 375 | |
| Number of Antidepressants (N06A), n (%) patients are exposed to | 369 | |||
| 0 | 430 (54) | 181 (57) | 249 (52) | |
| 1 | 256 (32) | 94 (30) | 162 (34) | |
| 2 | 97 (12) | 39 (12) | 58 (12) | |
| 3 | 14 (1.8) | 2 (0.6) | 12 (2.5) | |
| 4 | 2 (0.3) | 1 (0.3) | 1 (0.2) | |
| Number of Antiepileptics (N03A), n (%), n (%) patients are exposed to | 258 | |||
| 0 | 540 (68) | 230 (73) | 310 (64) | |
| 1 | 184 (23) | 56 (18) | 128 (27) | |
| 2 | 55 (6.9) | 25 (7.9) | 30 (6.2) | |
| 3 | 19 (2.4) | 6 (1.9) | 13 (2.7) | |
| 4 | 1 (0.1) | 0 (0) | 1 (0.2) | |
| Number of Antipsychotics (N05A, including lithium), n (%) patients are exposed to | 690 | |||
| 0 | 109 (14) | 92 (29) | 17 (3.5) | |
| 1 | 169 (21) | 106 (33) | 63 (13) | |
| 2 | 244 (31) | 78 (25) | 166 (34) | |
| 3 | 161 (20) | 32 (10) | 129 (27) | |
| 4 | 74 (9.3) | 4 (1.3) | 70 (15) | |
| 5 | 29 (3.6) | 2 (0.6) | 27 (5.6) | |
| 6 | 5 (0.6) | 0 (0) | 5 (1.0) | |
| 7 | 7 (0.9) | 3 (0.9) | 4 (0.8) | |
| 11 | 1 (0.1) | 0 (0) | 1 (0.2) | |
| Number of Hypnotics excl. benzodiazepines (N05C), n (%) patients are exposed to | 196 | |||
| 0 | 604 (76) | 229 (72) | 375 (78) | |
| 1 | 173 (22) | 77 (24) | 96 (20) | |
| 2 | 19 (2.4) | 9 (2.8) | 10 (2.1) | |
| 3 | 2 (0.3) | 1 (0.3) | 1 (0.2) | |
| 4 | 1 (0.1) | 1 (0.3) | 0 (0) | |
| Number of Anxiolytics incl. benzodiazepines (N05B), n (%) patients are exposed to | 144 | |||
| 0 | 655 (82) | 268 (85) | 387 (80) | |
| 1 | 121 (15) | 37 (12) | 84 (17) | |
| 2 | 17 (2.1) | 8 (2.5) | 9 (1.9) | |
| 3 | 6 (0.8) | 4 (1.3) | 2 (0.4) |